Published in Proc Natl Acad Sci U S A on April 03, 2006
LRRC26 auxiliary protein allows BK channel activation at resting voltage without calcium. Nature (2010) 1.89
BK potassium channel modulation by leucine-rich repeat-containing proteins. Proc Natl Acad Sci U S A (2012) 1.71
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A (2007) 1.41
Intermediate filaments: a role in epithelial polarity. Exp Cell Res (2007) 1.14
The LRRC26 protein selectively alters the efficacy of BK channel activators. Mol Pharmacol (2011) 1.03
CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis. Oncogene (2011) 0.98
Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis. Mol Cancer Res (2012) 0.92
Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. Sci Rep (2015) 0.79
The human cell surfaceome of breast tumors. Biomed Res Int (2013) 0.79
Non-AUG translational initiation of a short CAPC transcript generating protein isoform. Biochem Biophys Res Commun (2009) 0.77
Basic local alignment search tool. J Mol Biol (1990) 659.07
dbEST--database for "expressed sequence tags". Nat Genet (1993) 41.10
The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell (1982) 19.91
SMART: identification and annotation of domains from signalling and extracellular protein sequences. Nucleic Acids Res (1999) 11.33
Pathways for protein disulphide bond formation. Trends Cell Biol (2000) 2.51
Distinct compartmentalization of TGN46 and beta 1,4-galactosyltransferase in HeLa cells. Eur J Cell Biol (1997) 1.64
Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor. Biochimie (1986) 1.37
High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. Proc Natl Acad Sci U S A (1999) 1.34
Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer (2002) 1.33
Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc Natl Acad Sci U S A (2003) 1.22
Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res (2005) 1.14
De novo formation of cytokeratin filament networks originates from the cell cortex in A-431 cells. Cell Motil Cytoskeleton (2001) 0.93
In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochim Biophys Acta (2005) 0.90
An antigen unmasking protocol that satisfies both immunohistochemistry and subsequent PCR amplification. Pathol Res Pract (2003) 0.88
New approaches in identifying drugs to inactivate oncogene products. Semin Cancer Biol (2004) 0.88
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The diploid genome sequence of an individual human. PLoS Biol (2007) 44.80
The Sorcerer II Global Ocean Sampling expedition: northwest Atlantic through eastern tropical Pacific. PLoS Biol (2007) 23.58
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Large-scale transcriptional activity in chromosomes 21 and 22. Science (2002) 14.01
The Sorcerer II Global Ocean Sampling expedition: expanding the universe of protein families. PLoS Biol (2007) 13.99
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
A catalog of reference genomes from the human microbiome. Science (2010) 8.10
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Genetic variation in an individual human exome. PLoS Genet (2008) 6.68
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45
Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30
The dynamic genome of Hydra. Nature (2010) 4.00
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Long-range heterogeneity at the 3' ends of human mRNAs. Genome Res (2002) 3.91
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2011) 3.36
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Sequencing of Culex quinquefasciatus establishes a platform for mosquito comparative genomics. Science (2010) 3.18
Survey sequencing and comparative analysis of the elephant shark (Callorhinchus milii) genome. PLoS Biol (2007) 2.90
Genome sequences of the human body louse and its primary endosymbiont provide insights into the permanent parasitic lifestyle. Proc Natl Acad Sci U S A (2010) 2.76
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res (2005) 2.39
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol (2005) 2.33
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
ROC and confusion analysis of structure comparison methods identify the main causes of divergence from manual protein classification. BMC Bioinformatics (2006) 2.18
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int (2008) 2.14
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature (2002) 2.08
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res (2010) 2.01
Genetic and genomic tools for Xenopus research: The NIH Xenopus initiative. Dev Dyn (2002) 2.01
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 2.00
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res (2006) 1.99
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res (2011) 1.87
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
Distinct roles of segregated transmission of the septo-habenular pathway in anxiety and fear. Neuron (2013) 1.78
Podocyte injury damages other podocytes. J Am Soc Nephrol (2011) 1.75
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res (2008) 1.71
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
The interactive online SKY/M-FISH & CGH database and the Entrez cancer chromosomes search database: linkage of chromosomal aberrations with the genome sequence. Genes Chromosomes Cancer (2005) 1.70
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol (2004) 1.66
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res (2004) 1.65
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Human, mouse, and rat genome large-scale rearrangements: stability versus speciation. Genome Res (2004) 1.63
A binding domain on mesothelin for CA125/MUC16. J Biol Chem (2008) 1.61
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res (2010) 1.59
Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases. Proc Natl Acad Sci U S A (2004) 1.59
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res (2006) 1.57
Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury. Nephrol Dial Transplant (2013) 1.54
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2004) 1.54
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
Ancient noncoding elements conserved in the human genome. Science (2006) 1.53
Cancer Molecular Analysis Project: weaving a rich cancer research tapestry. Cancer Cell (2002) 1.53
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
A preliminary transcriptome map of non-small cell lung cancer. Cancer Res (2002) 1.42
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A (2007) 1.41
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res (2005) 1.39